Off-label use of rituximab for systemic lupus erythematosus in Europe

Date
2016
Author
Saez-Comet, Luis
Cervello, Gonzalo Salvador
Sebastiani, Gian Domenico
Squatrito, Danilo
Szucs, Gabriella
Caminal-Montero, Luis
Castro, Antoni
Colodro Ruiz, Agustin
Doria, Andrea
Domer, Thomas
Gonzalez-Echavarri, Cristina
Gremese, Elisa
Houssiau, Frederic A.
Huizinga, Tom
Isenberg, David
Luliano, Annamaria
Jacobsen, Soren
Jimenez-Alonso, Juan
Kovacs, Laszlo
Mariette, Xavier
Mosca, Marta
Nived, Ola
Oristrell, Joaquim
Ramos-Casals, Manuel
Rascon, Javier
Ruiz-Irastorza, Guillermo
Saez-Comet, Luis
Salvador Cervello, Gonzalo
Ruiz-Irastorza, Guillermo
Voskuyl, Alexandre
van Vollenhoven, Ronald
Inana, Murat
Ryden-Aulin, Monica
Boumpas, Dimitrios
Bultink, Irene
Rubio, Jose Luis Callejas
Metadata
Show full item record
Abstract
Objectives: Rituximab (RTX) is a biological treatment used off-label in patients with systemic lupus erythematosus (SLE). This survey aimed to investigate the off-label use of RTX in Europe and compare the characteristics of patients receiving RTX with those receiving conventional therapy.
URI
http://hdl.handle.net/20.500.12627/23419
https://doi.org/10.1136/lupus-2016-000163
Collections